Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407626 | 0.80 | FPR2 (0.34) | — | |
| SCHEMBL11493586 | 0.74 | ADRB2 (0.45) | — | |
| SCHEMBL3485397 | 0.72 | TDP1 (0.40) | ALDH1A1 | |
| SCHEMBL27800997 | 0.70 | POLB (0.46) | KDM4EALDH1A1MAPT | |
| SCHEMBL23595698 | 0.70 | — | — | |
| SCHEMBL23595697 | 0.70 | — | — | |
| SCHEMBL18575127 | 0.70 | SLC6A4 (0.32) | — | |
| SCHEMBL20680154 | 0.67 | — | — | |
| SCHEMBL8518650 | 0.67 | TDP1 (0.43) | NR5A2ALDH1A1MAPT | |
| SCHEMBL29594427 | 0.67 | NR5A2 (0.44) | NR5A2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197851-B1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-8513307-B2 | N-phenylacetamide inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20100273813-A1 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-28 | — | — | US | disclosed |
| EP-2197851-A1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030750-A1 | DERIVATIVES OF N-PHENYLACETAMIDE AS INHIBITORS OF THE ENZYME SOAT1 FOR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273813-A1 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | SOAT1, SOAT2, NAT1 | NR5A2 672/4885TRPA1 1341/4885KDM4E 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.